U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
26 févr. 2025 08h00 HE
|
Arcutis Biotherapeutics, Inc.
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
24 févr. 2025 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
13 nov. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
29 juil. 2024 07h35 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the signing of a co-promotion agreement with Kowa Pharmaceuticals America, Inc.
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
29 juil. 2024 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
22 juil. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis will host a KOL virtual event July 29, 2024
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
09 juil. 2024 16h53 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
01 avr. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
11 mars 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer.
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
09 mars 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
These findings are the first to characterize the unique molecular profile of seborrheic dermatitis